Quest, I have been very bullish on the potential this company has. However based on the recent quarterly and the commentary from the company, sometimes, some facts need to be listened to - do what you want with the investment, I'm not saying otherwise. I have $100,000 in this personally.
The recent activity is not strong. It is really nothing. A few pip trades intra day on extremely low volume is nothing. Look at the trade history:
Barely broken 5Million shares per day outside of the BARDA news on the 03/10 with 21Million shares and the 11Million dump on quarterly. We honestly need to see 50+Million A DAY traded to quantify momentum.
Volume determines the conviction of the movement and low volume increases are nothing. I could swing the share price north or south by 20%+ today if i wanted to. Fact is, I'm not and the volume would be insignificant to shift this the way people want it to go.
The company has had nothing but positive news after news after news - so why no increase? Constant cappers? No. We identified once it occurred that PVM was holding the price down to get out of their position. But since then, what else could it be outside of unhappy campers doing the same?
The company
needs to sell itself better if they want the SP to grow, but as they have advised, it is the last thing they care about. They are focussed on their "several year plan" for Febridx. That isn't something someone wants to hear given they have ramped the news about distributors and regions etc, reimbursement codes and so forth. To the ordinary punter, that means jack all. People on the ASX will primarily invest on 4 basic metrics imo:
- Good revenue figures
- Major agreements (partnerships with major players)
- Mergers / Acquisitions
- Lithium rock chip samples
Out of the 4 above, LDX has had several and its done bugger all to move this back to where it was post FDA approval.
The only thing and I mean the ONLY thing outside of a major deal with substantial ongoing revenue (ie. Hologic agreeing to pay Lumos $15M a year continuously at worst) is Febridx uptake because that is all they have pumped since its IPO.
They canned 2 other products in Sepsidx and Uridx, never to be seen again. Covidx went the way of the Dodo.
They have banked their business on Hologics FFN test and Febridx. Both of which seem 12 months away at best.
